Officials at Diamyd Medical say the company will install a new Cytiva FlexFactory platform in Umeå, Sweden. Once up and running, the clinical-stage biopharmaceutical company will begin manufacturing its precision-medicine type 1 diabetes vaccine, which works to reprogram immune cells to prevent the destruction of pancreatic insulin-producing B cells.

Globally, more than 1.1 million children and adolescents live with the autoimmune disease, type 1 diabetes, according to the International Diabetes Federation. Diamyd Medical develops therapies that target the underlying causes of diabetes.

“The importance of being in control of your own manufacturing process for biologics has never been so apparent as during the present pandemic,” said Ulf Hannelius, president and CEO, Diamyd Medical. “With FlexFactory we will be able to produce the biologic GAD, the active product ingredient in our diabetes vaccine. We chose Cytiva’s solutions thanks to the flexibility. The platform we use today can be transformed tomorrow to meet future growth and demand.”

“We developed our FlexFactory platform to be flexible and scalable so companies like Diamyd can respond to changing demands,” added Olivier Loeillot, vice president of bioprocess, Cytiva.

Previous articleCytovia Inks Two Deals Covering R&D and Biomanufacturing Operations
Next articleSangamo, Sanofi Show Positive Early Data for SCD Gene-Edited Cell Therapy